CD43 is a highly glycosylated transmembrane protein expressed on the surface of most hematopoietic cells. Expression of CD43 has also been demonstrated in many human tumor tissues, including colon adenomas and carcinomas, but not in normal colon epithelium. The potential contribution of CD43 to tumor development is still not understood. Here, we show that overexpression of CD43 increases cell growth and colony formation in mouse and human cells lacking expression of either p53 or ARF (alternative reading frame) tumor-suppressor proteins. In addition, CD43 overexpression also lowers the detection of the FAS death receptor on the cell surface of human cancer cells, and thereby helps to evade FAS-mediated apoptosis. However, when both p53 and ARF proteins are present, CD43 overexpression activates p53 and suppresses colony formation due to induction of apoptosis. These observations suggest CD43 as a potential contributor to tumor development and the functional ARF-p53 pathway is required for the elimination of cells with aberrant CD43 expression.
Abstract. The Wnt/β-catenin pathway regulates key cellular processes such as differentiation, proliferation, apoptosis; and its activation promotes development of several cancer types. Expression of CD43 (leukosialin), the predominant leukocyte transmembrane sialoglycoprotein, has been detected in many tumors of non-hematopoietic origin. CD43 participates in cell adhesion and regulates intracellular signal transduction pathways involved in cell proliferation and survival. The cytoplasmic domain of CD43 has been reported to translocate to the nucleus, interact with β-catenin and affect its target gene expression, but the impact of this action on cell fate is still unknown. We demonstrate, here, by colony formation assay and siRNA-mediated gene silencing that CD43 and β-catenin co-operate in promoting cell growth. Moreover, in cells with down-regulated β-catenin expression the activation of p53 in response to CD43 overexpression is significantly impaired. In addition, the presence of both CD43 and β-catenin is required for the TCF/LEF-mediated transcription. Presumably, the fulllength CD43 participates in this transcriptional regulation. We show that the mature CD43 localizes to the nucleus, where it binds chromatin, co-localizes and co-immunoprecipitates with β-catenin, and enhances the reporter gene expression regulated by β-catenin. These observations provide clear evidence linking CD43 to the Wnt/APC/β-catenin signaling pathway and supporting our hypothesis according to which CD43 plays a role in tumor development.
Abstract. CD43 (leukosialin, sialophorin), a cell surface protein on most hematopoietic cells, is an important regulator of immune cell function and is involved in regulation of cell adhesion and proliferation. Aberrant expression of CD43 is a common event observed in human tumors of non-hematopoietic origin suggesting a role in tumor development. We have previously shown that overexpression of CD43 causes activation of the ARF-p53 tumor-suppressor pathway and results in cell death. In a non-functional ARF-p53 background, the cells overexpressing CD43 display an increased cell growth rate due to higher survival. Here we show that p53 specifically downregulates the expression of CD43 at the protein and mRNA level. Transactivating properties of p53 are necessary to affect the expression of exogenous CD43. The downregulation of CD43 mRNA is caused by p53-dependent transrepression, at least in part, via a histone deacetylation mechanism. These studies establish that under certain conditions there exists a negative feedback loop between p53 and CD43: CD43-dependent signaling activates p53, which in turn downregulates the expression of CD43.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.